7,861 Shares in Smith & Nephew SNATS, Inc. $SNN Acquired by Kovitz Investment Group Partners LLC

Key Points

• Kovitz Investment Group Partners LLC has acquired a new stake in Smith & Nephew SNATS, Inc., totaling 7,861 shares valued at approximately $223,000.
• Several institutional investors, including Bessemer Group Inc. and GAMMA Investing LLC, have significantly increased their stakes or established new positions in Smith & Nephew during the first quarter.
• The firm's stock has seen a 1.5% increase recently, with a current valuation of $37.53 and a twelve-month high of $37.58.

Kovitz Investment Group Partners LLC acquired a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 7,861 shares of the medical equipment provider's stock, valued at approximately $223,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in SNN. Bessemer Group Inc. lifted its stake in shares of Smith & Nephew SNATS by 3,471.4% during the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock valued at $49,000 after acquiring an additional 1,701 shares during the period. Sequoia Financial Advisors LLC bought a new stake in Smith & Nephew SNATS during the 1st quarter worth about $211,000. GAMMA Investing LLC lifted its position in Smith & Nephew SNATS by 22.4% during the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock valued at $103,000 after purchasing an additional 666 shares during the period. BNP Paribas Financial Markets acquired a new position in Smith & Nephew SNATS during the 4th quarter valued at about $435,000. Finally, Barclays PLC bought a new position in shares of Smith & Nephew SNATS in the 4th quarter valued at about $431,000. Institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Trading Up 1.5%

SNN opened at $37.5330 on Friday. The firm's fifty day moving average is $31.96 and its two-hundred day moving average is $29.22. The firm has a market cap of $16.44 billion, a PE ratio of 17.38, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. Smith & Nephew SNATS, Inc. has a twelve month low of $23.69 and a twelve month high of $37.58. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.

Smith & Nephew SNATS Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be paid a dividend of $0.285 per share. This represents a yield of 210.0%. The ex-dividend date of this dividend is Friday, October 3rd. Smith & Nephew SNATS's dividend payout ratio (DPR) is presently 26.39%.

Analysts Set New Price Targets

A number of research firms recently weighed in on SNN. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research note on Friday. Canaccord Genuity Group upped their target price on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a "hold" rating in a research report on Monday, August 18th. HSBC downgraded Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Hsbc Global Res cut Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Six analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $36.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.